Our survival analysis revealed that NSCLC patients with Cx43-positive immunostaining in the nucleus had significantly shorter survival rates compared to those with Cx43-negative immunostaining or cytoplasmic immunostaining. The gene discussed is GJA1; the disease is non-small cell lung carcinoma.